Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,616.85
(
0.08%
)
US TECH 100
23,589.60
(
0.21%
)
Dow Jones
46,584.46
(
-0.18%
)
Brent Oil
101.37
(
-5.32%
)
Bitcoin
69,967.54
(
1.61%
)
News Focus
News Focus
Post# of 257369
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122853
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biotech jim post# 147640

Friday, 08/24/2012 7:53:24 AM

Friday, August 24, 2012 7:53:24 AM

Post# of 257369
LLY—Pooled secondary analyses do not a regulatory success make. Thus, Solanezumab is almost certainly a no-go without new phase-3 studies, which is something LLY will wisely be reluctant to undertake.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today